With respect to concurrent administration of HD IL-2 and CPI therapy, early feasibility was reported by Prieto et al. in an initial clinical study report and a 7-year follow-up of 36 melanoma patients treated with the combination of Ipi and HD IL-2 [25, 26]. The gene discussed is IL2; the disease is melanoma.